News
-
-
-
COMMUNIQUÉ DE PRESSE
ONWARD Medical publie ses résultats financiers et opérationnels pour l’exercice 2024 et partage ses faits marquants du début de l’année 2025
ONWARD Medical publie ses résultats financiers et opérationnels pour l’exercice 2024, annonce l'obtention de l'autorisation de la FDA et des premières ventes commerciales du système ARC-EX ainsi que d'autres faits marquants -
-
-
COMMUNIQUÉ DE PRESSE
ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital Increase with Cornerstone Investment from Ottobock SE & Co. KGaA
ONWARD® Medical raises EUR 50 million with strategic investment from Ottobock SE & Co. KGaA, extending cash runway. Ottobock acquires c.10% share capital, initiating collaboration for spinal cord injury therapies -
-
-
COMMUNIQUÉ DE PRESSE
ONWARD® Medical Launches Capital Increase for Indicative Amount of c. EUR 40 Million including EUR 22.5 Million Cornerstone Investment from Ottobock SE & Co. KGaA
ONWARD Medical launches capital increase of c. EUR 40 million with EUR 22.5 million cornerstone investment from Ottobock SE & Co. KGaA, aiming to develop spinal cord stimulation therapies for spinal cord injury patients -
